Danish Drama: Genmab Drops $8B on Cancer Cure Hope Seller
In a move that screams 'we have billionaire money to burn,' Danish biotech bigwig Genmab announced it plans to acquire Merus, the brainiac behind a shiny new head and neck cancer drug, for around $8 billion. That's $8 billion, or roughly the cost of buying every Danish pastry in Copenhagen twice over. This deal lands Genmab firmly in Life Sciences prime, scheming to turn biology into cold, hard kroner. With cancer therapy innovation like this on the line, letâs hope Merus's drug fights neck and head tumors better than Genmab fought that price tag.
Share the Story
(1 of 3)Genmab just dropped $8 billion on Merus like itâs Black Friday for biotech, apparently 'saving cancer patients' is easier when you have a billionaire bankroll appearing out of nowhere.
Buying a head and neck cancer drug developer for $8 billion is peak pharmaceutical flexâGenmabâs basically saying, 'Weâll fix your cells, but first, show us the money.'
Genmab buying Merus is like paying $8 billion for a Tesla upgradeâyouâre still hoping it doesnât break down, but hey, it looks promising!
Source: Statnews | Published: 9/29/2025 | Author: Andrew Joseph
More Articles in Business
Doom Devs Drop Hellfire Expansion While Xbox Drops Entire Team
South Korean Chipmaker Raises $26.5B While AI Gobbles All The RAM
Tesla Laughs as Other Automakers Slam Doors on EVs, Ride Gas Price Rollercoaster
NYC Hotelâs Kitchen Uses 2,000 Eggs Weekly to Feed Masses, Not Chickens
MrBeast's Candy Empire Faces Sugar Crash, Now Selling Ethics Instead of Joy
Man Trades Time For Money Then Tries To Retire Before Age 30, Shockingly
